Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Byon, MD, PhD
Imugene Limited
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Recruiting - Liverpool Hospital
Liverpool, New South Wales, Australia
Recruiting - Royal Adelaide Hospital
Adelaide, South Australia, Australia
Recruiting - St Vincent'S Hospital Melbourne
Fitzroy, Victoria, Australia
Matthew KuRecruiting - Barwon Health - Andrew Love Cancer Centre
Geelong, Victoria, Australia
Hannah RoseRecruiting
- Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Completed - City of Hope
Duarte, California, United States
Completed - H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Bijal Shah, MDRecruiting - Northside Hospital Cancer Institute
Atlanta, Georgia, United States
Scott Solomon, MDRecruiting - Winship Cancer Institute Emory University
Atlanta, Georgia, United States
Edmund Waller, MDRecruiting - University of Maryland
Baltimore, Maryland, United States
Jean Yared, MDRecruiting - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Completed - Tufts Medical Center
Boston, Massachusetts, United States
Andreas Klein, MDRecruiting - Barbara Ann Karmanos Cancer Institute (wayne State University)
Detroit, Michigan, United States
Completed - University of Minnesota
Minneapolis, Minnesota, United States
Supriya Gupta, MDRecruiting - Columbia University Irving Medical Center/new York Presbyterian Hospital
New York, New York, United States
Ran Reshef, MDRecruiting - Weill Cornell Medical College - Ny Presbyterian Hospital
New York, New York, United States
Completed - Duke University
Durham, North Carolina, United States
Completed - Ohio State University
Columbus, Ohio, United States
Completed - Lifespan Cancer Institute at Rhode Island Hospital
Providence, Rhode Island, United States
Adam Olszewski, MDRecruiting - Baylor University Medical Center
Dallas, Texas, United States
Houston Holmes III, MDRecruiting - Md Anderson
Houston, Texas, United States
Completed - Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Nirav Shah, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Mar 2019
- Primary completion
- 30 Jun 2027
- Completion
- 30 Jun 2027
- Last update posted
- 2 Feb 2026
- Registered enrollment
- 135
- Registry id
- NCT03666000
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.